Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection

Journal of Infectious Diseases

Volumn 199, Issue 11, 2009, Pages 1680-1688

  Gray, Richard T ^a   Beagley, Kenneth W ^b   Timms, Peter ^b   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; IMMUNOLOGICAL ADJUVANT; VACCINE;

ARTICLE; BACTERIAL GROWTH; BACTERIAL TRANSMISSION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE DURATION; EPIDEMIC; HEALTH PROGRAM; IMMUNE RESPONSE; INCIDENCE; INFECTION SENSITIVITY; MATHEMATICAL MODEL; MORBIDITY; PELVIC INFLAMMATORY DISEASE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SIMULATION; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HETEROSEXUALITY; HUMANS; IMMUNITY; MALE; MIDDLE AGED; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; TIME FACTORS; YOUNG ADULT;

EID: 67650661206     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598983     Document Type: Article

References (48)

1. -2004 Canadian sexually transmitted infections surveillance report. Can Commun Dis Rep 2007; 33(Suppl 1):l-69.
2. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2006 supplement. Chlamydia prevalence monitoring project: annual report 2006. Rev ed. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
3. Vajdic CM, Middleton M, Bowden FJ, Fairley CK, Kaldor KM. The prevalence of genital Chlamydia trachomatis in Australia 1997-2004: a systematic review. Sexual Health 2005; 2:169-83.
4. Wallace LA, Scoular A, Hart G, Reid M, Wilson P, Goldberg DJ. What is the excess risk of infertility in women after genital Chlamydia infection? A systematic review of the evidence. Sex Transm Infect 2008; 84:171-5.
5. Cunningham KA, Beagley KW. Male genital tract chlamydial infection: implications for pathology and infertility. Biol Reprod 2008; 79:180-9.
6. Farley TA, Cohen D, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med 2003; 36:502-9.
7. Brunham RC, Pourbohloul B, Mak S, White R, Rekat ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005; 192:1836-44.
8. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005;5:149-61.
9. Beagley KW, Timms P. Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development. J Reprod Immunol 2000;48:47-68.
10. Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985; 7:717-25.
11. Igietseme J, Eko F, He Q, Bandea C. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv 2005; 2:549-62.
12. Peipert JF. Genital chlamydial infections. N Engl J Med 2003; 349:2424 30.
13. Smith AMA, Rissel CE, Richters J, Grulich AE, de Visser RO. Australian study of health and relationships. Aust NZ J Public Health 2003; 27:103-256.
14. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea and Chlamydia using stochastic network simulations. Am J Epidemiol 1996; 144:306-17.
15. Harvey SM, Bird ST, Henderson JT, Beckman LJ, Huszti HC. He said, she said: concordance between sexual partners. Sex Transm Dis 2004; 31:185-91.
16. Catania JA, Canchola J, Binson D, et al. National trends in condom use among at-risk heterosexuals in the United States. J Acquir Immune Defic Syndr 2001; 27:176-82.
17. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Farn Plann Perspect 1999; 31:272-9.
18. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303-12.
19. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835-42.
20. Foxman B, Newman M, Percha B, Holmes KK, Aral SO. Measures of sexual partnerships: lengths, gaps, overlaps, and sexually transmitted infection. Sex Transm Dis 2006; 33:209-14.
21. Wiesenfeld HC, Hillier SL, Amortegui AJ, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456-63.
22. Patterson TL, Rank RG. Immunity to reinfection and immunization of male guinea pigs against urethral infection with the agent of guinea pig inclusion conjunctivitis. Sex Transm Dis 1996; 23:145-50.
23. Rank RG, Batteiger BE, Soderberg LS. Susceptibility to reinfection after a primary chlamydial genital infection. Infect Immun 1988; 56:2243-9.
24. Brunham RC, Rekart ML. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 2008; 35:53-4.
25. Australia. Health Insurance Commission. Medicare item 69369, processed from January 2003 to December 2003, and Medicare item 69370, processed from January 2003 to December 2003. Available at: https:// www.medicareaustralia.gov. au/statistics/mbs-item.shtml. Accessed 10 June 2008.
26. Chen MY, Ryder N, Donovan B. Completeness and timeliness of treatment for Chlamydia within a sexual health service. Int J STD AIDS 2004; 15:762-4.
27. Cook RL, Hutchinson SL, Ostergaard L, Braithwaite RS, Ness RB. Systematic reviw: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005; 142:914-25.
28. Kretzschmar M, Weite R, van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. Am J Epidemiol 2001; 153:90-101.
29. Regan DG, Wilson DP, Hocking JS. Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis 2008; 198: 349-58.
30. Rank RG, Bowlin AK, Reed RL, Darville T. Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose. Infect Immun 2003; 71:6148-54.
31. Molano MN, Meijer CJLM, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005; 191:907-16.
32. van Valkengoed IGM, Morré SA, van den Brule AJC, Meijer CJLM, Bouter LM, Boeke AJP. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes: implications for cost-effectiveness analyses. Int J Epidemiol 2004; 33:416-25.
33. Pal S, Theodor I, Peterson EM, et al. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 1997; 15:575-82.
34. Morrison SG, Morrison RP. A predominant role for antibody in ac-quired immunity to chlamydial genital tract reinfection. J Immunol 2005; 175:7536-42.
35. Srivastava P, Jha R, Bas S, Salhan S, Mittal A. In infertile women, cells from Chlamydia trachomatis infected sites release higher levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha upon heat-shock-protein stimulation than fertile women. Reprod Biol Endocrinol 2008; 6:20.
36. Barker CJ, Beagley KW, Hafner LM, Timms P. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. Vaccine 2008; 26:1285-96.
37. Crane DD, Carlson JH, Fischer ER, et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci USA 2006; 103:1894-9.
38. McNeilly CL, Beagley KW, Moore RJ, Haring V, Timms P, Hafner LM. Expression library immunization confers partial protection against Chlamydia muridarum genital infection. Vaccine 2007; 25: 2643-55.
39. Kinnunen A, Surcel HM, Halttunen M, et al. Chlamydia trachomatis heat shock protein-60 induced interferon-gamma and interleukin10 production in infertile women. Clin Exp Immunol 2003; 131:299-303.
40. Peeling RW, Kimani J, Plummer F, et al. Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. J Infect Dis 1997; 175:1153-8.
41. Eckert LO, Hawes SE, Wolner-Hanssen P, et al. Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. J Infect Dis 1997; 175:1453-8.
42. Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 1996; 276:1737-42.
43. Viscidi RP, Bobo L, Hook EW III, Quinn TC. Transmission of Chlamydia trachomatis among sex partners assessed by polymerase chain reaction. J Infect Dis 1993; 168:488-92.
44. Worm AM, Petersen CS. Transmission of chlamydial infections to sexual partners. Genitourin Med 1987; 63:19-21.
45. Lycke E, Lowhagen GB, Hallhagen G, Johannisson G, Ramstedt K. The risk of transmission of genital Chlamydia trachomatis infection is less than that of genital Neisseria gonorrhoeae infection. Sex Transm Dis 1980; 7:6-10.
46. Katz BP. Estimating transmission probabilities for chlamydial infection. Stat Med 1992; 11:565-77.
47. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
48. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-20.